Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03087071 · ClinicalTrials.gov registry record · Phase 2
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
A Phase 2 study of Metastatic Colorectal Adenocarcinoma and Stage IV Colorectal Cancer AJCC v7, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT03087071: Active Phase 2 study of Metastatic Colorectal Adenocarcinoma and Stage IV Colorectal Cancer AJCC v7, sponsored by M.D. Anderson Cancer Center.
NCT03087071 is a Phase 2 study of Metastatic Colorectal Adenocarcinoma and Stage IV Colorectal Cancer AJCC v7 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 59 participants, below the 84-participant average among 14 other Metastatic Colorectal Adenocarcinoma trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03087071, a Phase 2 study of Metastatic Colorectal Adenocarcinoma and Stage IV Colorectal Cancer AJCC v7, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II clinical trial studies how well panitumumab with or without trametinib works in treating patients with stage IV colorectal cancer. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving panitumumab with or without trametinib may work better in treating patients with stage IV colorectal cancer.
Primary Outcome
Will be evaluated along with the exact 95% confidence interval.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Trametinib
- BIOLOGICAL Panitumumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2017-12-29 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 2 |
What the registry record for NCT03087071 still lists
NCT03087071 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 84-participant average among 14 other Metastatic Colorectal Adenocarcinoma trials with a reported enrollment target (30% lower).
The record links to 8 conditions, with Metastatic Colorectal Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03087071 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03087071 about?
NCT03087071 is a clinical study titled "Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer". This phase II clinical trial studies how well panitumumab with or without trametinib works in treating patients with stage IV colorectal cancer. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's immune system attack the cancer, and may interfere with the ability of t...
What is the current status of trial NCT03087071?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2017-12-29. Estimated completion is 2027-01-31.
What conditions does trial NCT03087071 study?
This clinical trial studies the following conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, KRAS Gene Mutation.
What interventions are being tested in trial NCT03087071?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Trametinib (DRUG), Panitumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03087071?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03087071 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03087071's enrollment target sits among peer trials
59 6th of 14 higher than 9 of 14 other Metastatic Colorectal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Colorectal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
ACTIVE NOT RECRUITING · Phase 2
-
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
COMPLETED · Phase 2
-
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
RECRUITING · Phase 1
-
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI